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Uncoupling protein 3 (UCP3)The lipid peroxidation product 4-hydroxynonenal (HNE) increases the proton conductance of the inner
mitochondrial membrane through effects on uncoupling proteins (UCPs) and the adenine nucleotide
translocase (ANT); however, the relative contribution of the two carriers to these effects is unclear. To clarify
this we isolated mitochondria from skeletal muscle and heart of wild-type and Ucp3 knockout (Ucp3KO)
mice. To increase UCP3 expression, some mice were i.p. injected with LPS (12 mg/kg body weight). In spite
of the increased UCP3 expression levels, basal proton conductance did not change. HNE increased the proton
conductance of skeletal muscle and heart mitochondria. In skeletal muscle, this increase was lower in
Ucp3KO mice and higher in LPS-treated wild-type mice, and was partially abolished by GDP (UCPs inhibitor)
and completely abolished by carboxyatractylate (ANT inhibitor) or addition of both inhibitors. GDP had no
effect on HNE-induced conductance in heart mitochondria, but carboxyatractylate or administration of both
inhibitors had a partial effect. GDP-mediated inhibition of HNE-activated proton conductance in skeletal
muscle mitochondria was not observed in Ucp3KO mice, indicating that GDP is speciﬁc for UCP3, at least in
muscle. Carboxyatractylate was able to inhibit UCP3, probably through an indirect mechanism. Our results
are consistent with the conclusion that, in skeletal muscle, HNE-induced increase in proton conductance is
mediated by UCP3 (30%) and ANT, whereas in the heart the increase is mediated by ANT and other carriers,
possibly including UCP3.HNE, 4-hydroxynonenal; LPS,
nylenediamine; TPMP, triphe-
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It is well-established that the function of uncoupling protein 1
(UCP1) is adaptive thermogenesis in brown adipose tissue [1–3];
UCP1-catalyzed passive proton conductance increases respiration and
heat production by returning protons pumped by the respiratory
chain to the mitochondrial matrix without ATP synthesis. UCP1
activity is tightly regulated, being inhibited by purine nucleotides and
activated by free fatty acids. UCP3, another UCP family member, is
expressed most abundantly in the mitochondria of skeletal muscle
and to a lesser extent in heart and brown adipose tissue [4,5]. Proton
conductance through UCP3 can be activated by fatty acids [6,7],
superoxide [8] and the lipid peroxidation product 4-hydroxynonenal
(HNE) [9]. Given its high amino acid sequence identity to UCP1
(57%), UCP3 was initially proposed to perform a similar thermogenicfunction in skeletal muscle. However, mice lacking UCP3 maintain
their body temperature in a cold environment [10,11], indicating that
UCP3 is not required for cold-induced thermogenesis.
Among several functions proposed for UCP3, one that is gaining
support is a protective action against oxidative damage [12–15].
Mitochondrial membrane potential correlates strongly with ROS
production [16–19], and a small decrease in membrane potential
(mild uncoupling) was therefore suggested to have a natural
antioxidant effect [20]. In other words, mild uncoupling of oxidative
phosphorylation would protect against oxidative stress by decreasing
mitochondrial ROS production. The initial connection between UCPs
and ROS suggested by Negre-Salvayre et al. in 1997 [21] was
reinforced 5 years later with the identiﬁcation of superoxide as an
activator of UCPs [8]. Moreover, HNE, an important mediator of free
radical damage [22], speciﬁcally induces uncoupling of mitochondria
through UCPs 1, 2 and 3 and the adenine nucleotide translocase (ANT)
[9]. ANT, themost abundant carrier protein of themitochondrial inner
membrane, mediates half to two-thirds of basal proton conductance
[12] and catalyses an inducible proton leak in the presence of fatty
acids [23,24], AMP [25] or HNE [9,26]. HNE decreases ROS production
by inducing UCP and ANT mediated uncoupling, and this has been
proposed as a feedback mechanism to protect against ROS damage.
This induction requires a high protonmotive force [26,27]. A simple
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superoxide production generates carbon-centred radicals that initiate
lipid peroxidation, producing alkenals such as HNE that activate UCPs
and ANT [28–30]. However, the mechanism by which these inter-
mediates activate the UCPs has not been characterized. In addition,
activation of UCPs by superoxide or HNE has not been veriﬁed by
other groups [13,31,32].
Inducible proton conductance catalyzed by ANT is inhibited by
carboxyatractylate, bongkrekic acid, and the ANT substrates ADP and
ATP, but not by other nucleotides. UCPs, in contrast, are inhibited by
purine nucleotides, including not only ATP and ADP but also by GDP
and GTP [25]. For this reason GDP has beenwidely used as a diagnostic
inhibitor of UCP function in vitro [33–36]. However, the speciﬁcity of
GDP and carboxyatractylate has recently been questioned [37–39].
The purpose of the present study was to determine the UCP3
speciﬁcity of HNE-induced uncoupling in skeletal muscle and heart
mitochondria. We evaluated proton leak kinetics in the presence of
HNE in wild-type and Ucp3KO mice treated with or without LPS,
which induces UCP3 expression. We examined the inhibition of HNE-
induced activation of proton conductance by an inhibitor considered
speciﬁc for UCPs (GDP), an inhibitor considered speciﬁc for ANT
(carboxyatractylate) and both inhibitors simultaneously. HNE-in-
duced increase in proton conductancewas proportional to the content
of UCP3 in skeletal muscle but not in heart mitochondria, and was
mediated by UCP3 (30%) and ANT in muscle, and by ANT and other
carriers in heart. GDP speciﬁcally inhibits UCP3, at least in muscle,
whereas carboxyatractylate inhibits ANT and possibly other carriers,
including UCP3.
2. Materials and methods
2.1. Animals and treatments
Wild-type and UCP3 knockout mice [10] were generated from
three pairs of UCP3 heterozygous mice (C56Bl/6J) in our breeding
colony. Ucp3KO was conﬁrmed by PCR analysis of skeletal muscle and
heart mitochondria. Mice were maintained at 22 °C on a 12:12 h
light–dark cycle and were fed normal rodent chow (5K54 JL Rat and
Mouse/Auto 4F, LabDiet) and water ad libitum. Eight- to 10-week-old
male and female mice were used for all studies. A working stock of
lipopolysaccharide (LPS) from E. coli 055:B5 (Sigma) was prepared in
sterile PBS, and aliquots were frozen at−20 °C and thawed on the day
of the experiment. Mice were i.p. injected with LPS at 12 mg/kg body
weight (control mice were injected with sterile PBS). After injection,
mice were given free access to food and water.
2.2. Isolation of mitochondria from skeletal muscle and heart
Twenty-four hours after LPS injection, mice were killed by cervical
dislocation, and hind limb muscles were immediately dissected and
placed in isolation medium containing 100 mM KCl, 50 mM Tris–HCl,
2 mM EGTA, pH 7.4, on ice. Mitochondria were prepared from 3 mice
per preparation essentially as described previously [40], with all steps
at 4 °C. Tissue was shredded with a sharp blade, minced with sharp
scissors, rinsedwith isolationmedium 4–5 times, and stirred for 2 min
in isolation buffer: 100 mM KCl, 50 mM Tris–HCl, 2 mM EGTA, 1 mM
ATP, 5 mM MgCl2, 0.5% (w/v) bovine serum albumin (BSA) and 10
units of protease/g of tissue (Sigma), pH 7.4. Tissue samples were
then gently homogenized with a glass tissue homogenizer. The
homogenate was centrifuged at 490× g for 10 min. The supernatant
was ﬁltered through muslin and centrifuged at 10368× g for 10 min.
Mitochondrial pellets were resuspended in isolation buffer, combined,
and centrifuged at 10368×g for 10 min and then at 3841×g for
10 min, and resuspended in 150 μl of isolation buffer.
Heart mitochondria were isolated as follows: hearts (8 per
preparation) were immediately extracted and placed on ice inisolation buffer, containing 230 mM mannitol, 70 mM sucrose, 5 mM
Tris–HCl and 1 mM EDTA, pH 7.4 [41]. Dissected ventricles were
minced with sharp scissors, washed 5–6 times in isolation buffer to
eliminate as much blood as possible, and incubated for 2 min in
isolation buffer supplemented with 40 units of protease/g tissue
(Sigma). The whole process was performed at 4 °C. Tissue samples
were gently homogenized with a glass tissue homogenizer, then
ﬁltered and centrifuged as for muscle (described above). Final pellets
were resuspended in 100 μl isolation buffer. Protein concentrations of
mitochondrial preparations were determined by the biuret method
using BSA as the standard.
2.3. Immunoblot analysis of UCP3, ANT and complex IV expression
Total protein extracts were prepared in RIPA buffer (Sigma Aldrich
Chemical) supplemented with 1 mM dithiothreitol, 100 mM pefa-
block (Roche Diagnostics, Barcelona, Spain), pH 7.4, and a tablet of
protease-inhibitor cocktail (Roche Diagnostics). Tissue samples were
homogenized with a Polytron homogenizer and incubated on ice for
20 min. Tissue extracts were centrifuged at 12000× g for 10 min at
4 °C and the supernatants centrifuged again. Samples of the super-
natants were removed for protein determination (biuret method) and
the reminder stored at−80 °C. Equal amounts of each protein sample
(100 μg for UCP3 and ANT; 10 μg of muscle or 40 μg of heart protein
for complex IV) were resolved by SDS/12%-(w/v)-PAGE and
transferred to PVDF membranes (Amersham Biosciences, Buckin-
ghamshire, UK) by standard procedures. Membranes were blocked
with 5% (w/v) non-fat dry milk in TBS-T (20 mM Tris–HCl, pH 7.2,
150 mM NaCl, 0.1% Tween 20) and incubated overnight with a
polyclonal anti-UCP3 antibody (1:1000; PA1-055; Afﬁnity BioRea-
gents Inc., Golden, CO, USA) or a polyclonal anti-ANT antibody
(1:1000; sc-9299; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
in blocking solution at 4 °C. The anti-OxPhos complex IV subunit I
monoclonal antiboby (459600; Invitrogen) and the anti-porin
monoclonal antibody (456000; Invitrogen) were used at 1:5000 and
1:30000, respectively. Protein bands were detected by incubation for
1 h with the appropriate secondary antibody, horseradish peroxidase-
coupled goat anti-rabbit IgG (PI-1000; Vector Laboratories, Burlin-
game, CA, USA) or goat anti-mouse IgG (sc2005; Santa Cruz
Biotechnology) in blocking solution at room temperature, followed
by enhanced chemiluminescence (ECL®; GE Healthcare, Buckingham-
shire, UK).
2.4. Measurement of oxygen consumption
Oxygen consumption was measured using a Clark-type oxygen
electrode (Rank Brothers Ltd., Bottisham, Cambridge, UK) maintained
at 37 °C and calibrated with air-saturated assay buffer (120 mM KCl,
5 mM KH2PO4, 3 mM HEPES, 1 mM EGTA, and 0.3% (w/v) defatted
BSA, pH 7.2) which was assumed to contain 406 nmol O/ml at 37 °C
[42]. Electrode linearity was routinely checked by monitoring the
uncoupled respiration rate in the presence of 0.2 μM FCCP from 100%
to 0% air saturation. Mitochondria from skeletal muscle (0.35 mg
protein/ml) or heart (0.25 mg protein/ml) were incubated in assay
buffer containing 5 μM rotenone and 4 mM succinate. Respiratory
control ratios (RCR) were calculated as the State 3 respiration rate
with 250 μMADP divided by State 4 rate after ADP phosphorylation in
the presence of oligomycin (1 μg/ml).
2.5. Measurement of complex IV activity
Complex IV activity in active State 3 was estimated from the rate
of oxygen consumption of isolated mitochondria in the presence
of the artiﬁcial electron donors TMPD (N,N,N′,N′-tetramethyl-p-
phenylenediamine) and ascorbate by high-resolution respirometry
(Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria). Oxygraph-
Table 1
State 3 and State 4 respiratory rates and respiratory control ratio (RCR) in skeletal
muscle mitochondria from wild-type, LPS-treated wild-type, Ucp3KO and LPS-treated
Ucp3KO mice.
State 3 State 4 RCR
(nmol O2⋅min−1⋅mg
protein−1)
(nmol O2⋅min−1⋅mg
protein−1)
WT 240±19.7 61.8±5.89 3.69±0.16
WT+LPS 202±13.10 50.2±4.02 3.77±0.18
KO 229±5.10 70.8±3.26 3.30±0.14
KO+LPS 205±14.39 59.1±4.13# 3.48±0.11
Respiratory rates were determined in skeletal muscle mitochondria (0.35 mg protein/
ml) from wild-type (WT), LPS-treated wild-type (WT+LPS), Ucp3KO (KO) and LPS-
treated Ucp3KO (KO+LPS) mice, using rotenone (2 μM) to inhibit Complex I and
succinate (4 mM) as substrate; State 3 is the rate in the presence of 250 μM ADP and
State 4 is the nonphosphorylating rate in the presence of oligomycin (1 μg/ml); RCR is
the State 3/State 4 ratio. Measurements were made at 37 °C. Values represent means±
SEM from 8 independent experiments (#Pb0.05 vs. Ucp3KO).
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KH2PO4, 3 mM HEPES, 1 mM EGTA, and 0.3% (w/v) defatted BSA, pH
7.2) at 37 °C. The instrumental background ﬂux was calculated as a
linear function of oxygen concentration and the experimental data
were corrected using DatLab software (Oroboros Instruments) [43].
Mitochondria from skeletal muscle or heart (50 μg protein/ml) were
incubated in assay buffer containing 1 mM ADP, 10 μM cytochrome c,
2.5 μM antimycin A (to inhibit Complex III), 500 μM TMPD and 2 mM
ascorbate. Oxygen consumption was corrected for chemical back-
ground due to TMPD autoxidation [44].
2.6. Measurement of proton conductance
The rate at which protons return to the mitochondrial matrix is
proportional to the respiration rate in the presence of oligomycin (an
ATPase inhibitor). Therefore, to measure proton conductance, we
determined oxygen consumption and membrane potential simulta-
neously, using electrodes sensitive to oxygen (Rank Brothers Ltd.,
Bottisham, Cambridge, UK) and to the potential-dependent probe
TPMP+ (triphenylmethylphosphonium). The TPMP+ electrode was
constructed as previously described [45]. Mitochondria from skeletal
muscle (0.35 mg/ml protein) or heart (0.25 mg/ml protein) were
incubated in assay buffer containing 5 μM rotenone, 1 μg/ml oligo-
mycin, and 100 nM nigericin (to collapse the difference in pH across
the inner membrane). The electrode was calibrated with sequential
0.5 μM additions of TPMP up to 2.5 μM, and 4 mM succinate was thenFig. 1. Immunoblot analysis of the expression levels of UCP3 and ANT proteins in whole tiss
(KO) and LPS-treated Ucp3KO (KO+LPS) mice: (A and B) skeletal muscle and (C and D) hear
equal protein loading. Bar graphs show average protein expression. Data are means±SEMadded to start the reaction. Respiration and potential were progres-
sively inhibited through successive steady states by additions of
malonate up to 2.3 mM. At the end of each run, 0.2 μM FCCP was
added to dissipate the membrane potential and release all TPMP
back to the medium, allowing correction for any small electrode drift.
The TPMP binding correction for skeletal muscle was taken to be 0.35
(μl/mg protein)−1 [46]. When appropriate, 35 μM HNE (Cayman
Chemical, Ann Arbor, MI, USA) was added before TPMP calibration [9].ue and mitochondria from wild-type (WT), LPS-treated wild-type (WT+LPS), Ucp3KO
t. Immunoblot with anti-actin (tissue) or anti-porin (mitochondria) antibody conﬁrmed
from at least 3 independent experiments (*Pb0.05, **Pb0.01, ***Pb0.001 vs. WT).
Table 2
State 3 and State 4 respiratory rates and respiratory control ratio (RCR) in heart
mitochondria from wild-type, LPS-treated wild-type, Ucp3KO and LPS-treated Ucp3KO
mice.
State 3 State 4 RCR
(nmol O2⋅min−1⋅mg
protein−1)
(nmol O2⋅min−1⋅mg
protein−1)
WT 262±11.8 69.0±3.13 3.80±0.03
WT+LPS 231±6.13* 63.0±1.60 3.67±0.06
KO 275±14.40 72.1±4.47 3.83±0.10
KO+LPS 203±9.47### 54.8±1.76## 3.70±0.11
Respiratory rates were determined in heart mitochondria (0.25 mg protein/ml) from
wild-type (WT), LPS-treated wild-type (WT+LPS), Ucp3KO (KO) and LPS-treated
Ucp3KO (KO+LPS) mice, using rotenone (2 μM) to inhibit Complex I and succinate
(4 mM) as substrate; State 3 is the rate in the presence of 250 μMADP and State 4 is the
nonphosphorylating rate in the presence of oligomycin (1 μg/ml); RCR is the State 3/
State 4 ratio. Measurements were made at 37 °C. Values represent means±SEM from
8 independent experiments (*Pb0.05 vs. WT; ##Pb0.01, ###Pb0.001 vs. Ucp3KO).
1719E. Aguirre, S. Cadenas / Biochimica et Biophysica Acta 1797 (2010) 1716–1726When appropriate, the inhibitors GDP (500 μM; pre-incubated for
5 min) and carboxyatractylate (2.5 μM; pre-incubated for 1 min)
were added before HNE addition. All reagents were from Sigma unless
otherwise stated. Endogenous activation of proton conductance has
recently been reported in skeletal muscle mitochondria incubated at
high membrane potential [38]. To avoid erroneous results due to this
effect, proton leak curves from each groupwere obtained in duplicate,
in forward and reverse order, in each experiment.
2.7. Statistics
The statistical signiﬁcance of differences between groups was
determined by Student's t test. The level of signiﬁcance was set at
Pb0.05.
3. Results
3.1. Expression of UCP3 and ANT in skeletal muscle and heart
mitochondria from LPS-treated mice
UCP3 protein was detected in skeletal muscle and heart fromwild-
type (WT) mice but not Ucp3KO animals (Fig. 1), conﬁrming the
knockout status of these mice and the speciﬁcity of the antibody.
Treatment with LPS (12 mg/kg body weight) 24 h before tissue
extraction signiﬁcantly increased the expression of UCP3 in skeletal
muscle and heart of WT mice by 1.5–1.8 fold, as determined byFig. 2. Immunoblot analysis of the expression levels of complex IV (A and B) and complex IV
wild-type (WT), LPS-treated wild-type (WT+LPS), Ucp3KO (KO) and LPS-treated Ucp3KO (K
Data are means±SEM from 5 to 8 independent experiments (*Pb0.05 vs. WT; #Pb0.05 vs.western blot (Fig. 1). The absence of UCP3 protein did not lead to
compensatory increases in adenine nucleotide translocase (ANT)
expression (also reported for skeletal muscle in [39]), with ANT
expression levels similar in untreated and LPS-treated (24 h) WT or
Ucp3KO animals (Fig. 1).
3.2. Oxygen consumption and respiratory control ratio (RCR) in skeletal
muscle and heart mitochondria from LPS-treated mice
Respiration rates in State 3 and State 4 in mitochondria from LPS-
treated mice had a tendency to be lower than in those from untreated
mice (Tables 1 and 2). This effect was not statistically signiﬁcant in
skeletal muscle (except for LPS-treated Ucp3KO mice in State 4;
Table 1) but was signiﬁcant in the heart (except for LPS-treated WT
mice in State 4; Table 2). The respiratory control ratio (RCR) for WT
muscle mitochondria was 3.69±0.16 (n=8) and that for WT heart
mitochondria was 3.80±0.03 (n=8), consistent with the values
widely reported in the literature. There were no statistically
signiﬁcant differences in any tissue between WT and Ucp3KO
mitochondria or between mitochondria from untreated and LPS-
treated mice (Tables 1 and 2).
3.3. Effect of LPS on complex IV content and activity
Since State 3 and State 4 respiration rates had a tendency to be
lower in mitochondria from LPS-treated mice (Tables 1 and 2), we
determined complex IV content and activity in mitochondria isolated
from the four groups of mice. Although complex IV protein content
did not change in any case (Fig. 2A and B), its activity was signiﬁcantly
reduced in skeletal muscle (Fig. 2C) and heart (Fig. 2D) mitochondria
from LPS-treated mice.
3.4. Effect of UCP3 expression levels on basal proton conductance
There were no apparent differences between WT and Ucp3KO
proton conductance in skeletal muscle mitochondria in the absence of
activators (Fig. 3A). However, the quantiﬁcation as the difference
between rates from WT and Ucp3KO mice at 145 mV revealed a
∼5 mV difference (Fig. 3D). There were no differences between WT
and Ucp3KO basal proton conductance in heart mitochondria (Fig. 6A)
following a similar calculation (not shown). Although LPS treatment
increased the expression of UCP3 in WT mice (Fig. 1), this treatment
did not increase mitochondrial proton conductance in skeletal muscle
(Fig. 3B) or heart (Fig. 6B). As expected, LPS had no effect on UCP3activity (C and D) in skeletal muscle (A and C) and heart (B and D) mitochondria from
O+LPS) mice. Immunoblot with anti-porin antibody conﬁrmed equal protein loading.
Ucp3KO).
Fig. 3. Effects of HNE (35 μM) on the rate of proton leak in skeletal muscle mitochondria from (A) wild-type and Ucp3KO mice, (B) wild-type and LPS-treated wild-type mice, and
(C) Ucp3KO and LPS-treated Ucp3KO mice. All measurements were made in the presence of 0.3% BSA. Relevant curves in panel A are repeated in panels B or C to aid comparison. Bar
graphs on the right show the proton leak by interpolation at 145 mV. (D) Contribution of UCP3 to HNE-induced proton conductance in skeletal muscle mitochondria. Proton leak due
to UCP3 measured by interpolation of leak curves presented in Fig. 2A at 145 mV; bars represent the difference between respiration rates in WT and Ucp3KO mitochondria under
basal conditions and after stimulation with HNE. Data (A–C) are means±SEM from 6 to 10 independent experiments, each performed in duplicate (**Pb0.01, ***Pb0.001 vs. WT;
###Pb0.001 vs. Ucp3KO or WT+LPS; ††Pb0.01 vs. Ucp3KO+LPS; §Pb0.05 vs. WT+HNE). Data (D) are means±SEM from 10 independent experiments (***Pb0.001 vs. basal
conductance).
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Fig. 4. Effects of GDP (0.5 mM) and carboxyatractylate (CAT; 2.5 μM) on the rate of HNE-induced proton leak in wild-type skeletal muscle mitochondria. All measurements
were made in the presence of 0.3% BSA. Experiments were performed in skeletal muscle mitochondria from (A) wild-type and (B) LPS-treated wild-type mice. Bar graphs on the
right show the proton leak by interpolation at 145 mV. Data are means±SEM from 8 independent experiments, each performed in duplicate (*Pb0.05, **Pb0.01, ***Pb0.001 vs. WT
or WT+LPS; §Pb0.05, §§Pb0.01 vs. WT+HNE or WT+LPS+HNE).
Fig. 5. Effects of GDP (0.5 mM) and carboxyatractylate (CAT; 2.5 μM) on the rate of HNE-induced proton leak in Ucp3KO skeletal muscle mitochondria. All measurements were made
in the presence of 0.3% BSA. Experiments were performed in skeletal muscle mitochondria from (A) Ucp3KO and (B) and LPS-treated Ucp3KO mice. Bar graphs on the right show the
proton leak by interpolation at 145 mV. Data are means±SEM from 6 independent experiments, each performed in duplicate (**Pb0.01, ***Pb0.001 vs. Ucp3KO or Ucp3KO+LPS;
§Pb0.05 vs. Ucp3KO+HNE or Ucp3KO+LPS+HNE).
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and 6C).
3.5. Effect of HNE on mitochondrial uncoupling
The effect of HNE was studied in mitochondria from skeletal
muscle (Fig. 3) and heart (Fig. 6) of untreated and LPS-treatedWT and
Ucp3KOmice. HNE increased the proton conductance in mitochondria
from both tissues in all four experimental groups. In skeletal muscle,
this increase was larger in WT than in Ucp3KO mice (Fig. 3A),
indicating that UCP3 is involved in this effect. Fig. 3D shows proton
leak through UCP3 as the difference between rates from WT and
Ucp3KO mice at 145 mV. In contrast, in heart mitochondria the effect
of HNE was similar in WT and Ucp3KO mice (Fig. 6A). The increase in
proton conductance induced by HNEwas higher in the skeletalmuscle
of LPS-treated WT mice than in untreated controls (Fig. 3B), againFig. 6. Effects of HNE (35 μM) on the rate of proton leak in heart mitochondria from (A) wild
and LPS-treated Ucp3KOmice. All measurements weremade in the presence of 0.3% BSA. Rele
right show the proton leak by interpolation at 150 mV. Data are means±SEM from 6 indep
Ucp3KO or WT+LPS; †††Pb0.001 vs. Ucp3KO+LPS).suggesting the involvement of UCP3. Therewas no difference between
LPS-treated and control mice in HNE-induced proton conductance in
heart mitochondria (Fig. 6B and C).
3.6. Effect of GDP and carboxyatractylate on HNE-induced uncoupling
The HNE-induced increase in proton conductance in skeletal
muscle mitochondria from WT mice was partially inhibited by GDP
and totally inhibited by carboxyatractylate or both inhibitors (Fig. 4A).
In skeletal muscle mitochondria from LPS-treated WT mice, GDP and
carboxyatractylate only partially inhibited the HNE effect, and
addition of both inhibitors was necessary to completely abolish it
(Fig. 4B). GDP had no effect on HNE-induced proton conductance in
untreated or LPS-treated Ucp3KO mice; however, the HNE effect
was completely abolished by addition of carboxyatractylate or both
inhibitors (Fig. 5A and B).-type and Ucp3KO mice, (B) wild-type and LPS-treated wild-type mice, and (C) Ucp3KO
vant curves in panel A are repeated in panels B or C to aid comparison. Bar graphs on the
endent experiments, each performed in duplicate (***Pb0.001 vs. WT; ###Pb0.001 vs.
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mitochondria from untreated or LPS-treated WT mice (Fig. 7A and B),
despite the presence of increased UCP3 expression in the LPS-treated
animals (Fig. 1C and D). The same was true in heart mitochondria
from Ucp3KO mice (Fig. 8). Addition of carboxyatractylate partially
inhibited HNE effects on heart mitochondria from all four experi-
mental groups, and the effect was similar when carboxyatractylate
was added together with GDP (Figs. 7 and 8). Thus the addition of
both inhibitors did not completely prevent HNE-induced increase in
proton conductance in heart mitochondria.
4. Discussion
4.1. UCP3 does not contribute to basal proton conductance of heart
mitochondria and only minimally of skeletal muscle mitochondria
Despite initial reports showing a positive correlation between
UCP3 expression and basal mitochondrial proton conductance [10,11],
it is generally accepted that the UCP1 homologues UCP2 and UCP3 do
not increase proton conductance in the absence of activators, as
indicated by the fact that knockdown of UCP2 or 3 does not affect
basal proton conductance of mouse mitochondria [8,9,31,47,48].
Conﬁrming our previous results [8,47], we show here that the
respiratory control ratio (RCR) (Table 1) and proton conductance
(Fig. 3A) are similar in the skeletal muscle of WT and Ucp3KO mice;
moreover, our results show that this is also the case for heart
mitochondria (Table 2 and Fig. 6A). However, quantiﬁcation of the
difference between rates from WT and Ucp3KO mice at 145 mV
(Fig. 3A) reveals a minimal contribution (∼5 mV) of UCP3 to basal
proton conductance of skeletal muscle mitochondria (Fig. 3D). This is
consistent with a recent report [27]. Treatment with endotoxin, whichFig. 7. Effects of GDP (0.5 mM) and carboxyatractylate (CAT; 2.5 μM) on the rate of HNE-ind
presence of 0.3% BSA. Experiments were performed in heart mitochondria from (A) wild-typ
interpolation at 150 mV. Data aremeans±SEM from 6 independent experiments, each perfor
vs. WT+HNE or WT+LPS+HNE).increased UCP3 expression, did not alter the RCR (Tables 1 and 2)
or basal proton conductance (Figs. 3B, 3C, 6B and 6C) in muscle or
heart mitochondria. The lower respiration rates in State 3 and State 4,
and the lower activity of complex IV in LPS-treated mice are probably
due to endogenous production of nitric oxide (NO), since LPS induces
the expression of the inducible isoform of NO synthase (iNOS) [49,50]
and NO is a potent inhibitor of cytochrome c oxidase (complex IV) of
the electron transport chain [51–53]. This effect of NO has been
observed before in the liver of LPS-treated rats [54].
LPS treatment or sepsis have been shown to modify the expression
levels of UCP2 in liver [55] and of UCP3 in skeletal muscle [56,57]. This
effect is probably mediated by the pro-inﬂammatory cytokine TNF-α
[55,58,59]. Yu et al. [56] found no differences in mouse muscle proton
conductance 16 h after LPS injection (6 mg/kg body weight), though
they did detect an increase in UCP3 mRNA expression. In agreement
with this, we found no difference in basal proton conductance (in the
absence of activators) between control and LPS-treated mice in
muscle (Fig. 3B and C) and heart (Fig. 6B and C), despite the fact that
LPS treatment increased UCP3 levels (Fig. 1).
4.2. HNE increases mitochondrial proton conductance in skeletal muscle
and heart mitochondria: Inﬂuence of UCP3 content
In skeletal muscle, the HNE-induced increase in proton conduc-
tance was dependent on UCP3 expression levels, regardless of the
means (genetic or physiological) by which UCP3 content was varied.
Thus, it was higher in mitochondria from WT mice than Ucp3KO
animals (Fig. 3A) and even higher in LPS-treated WT mice (Fig. 3B).
The greater effect of HNE in WT muscle agrees with published data
[9,27]. In one of these studies, Parker et al. [27], by interpolation at a
membrane potential value of 160 mV, calculated the contribution ofuced proton leak in wild-type heart mitochondria. All measurements were made in the
e and (B) LPS-treated wild-type mice. Bar graphs on the right show the proton leak by
med in duplicate (*Pb0.05, **Pb0.01, ***Pb0.001 vs.WT orWT+LPS; §Pb0.05, §§Pb0.01
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ref. [27]). A similar calculation with our data (Fig. 3A) shows
the contribution of UCP3 to HNE-induced proton conductance
(at 145 mV) to be 30% (Fig. 3D). Thus, under our experimental
conditions, the contribution of UCP3 to HNE-induced proton conduc-
tance was ∼20% higher than previously reported, despite the fact that
the membrane potential used for our measurements was 15 mV
lower, and that HNE effects require a high membrane potential [27]. It
is worth noting that a previous report attributed to UCP3 50% of the
increase in HNE-activated proton conductance of skeletal muscle
mitochondria [9]. In the heart, however, there were no differences in
HNE-induced proton conductance between WT and Ucp3KO mice
(Fig. 6A) or between untreated and LPS-treated WT mice (Fig. 6B).
This indicates that UCP3 does not play a signiﬁcant role in HNE-
induced proton conductance in the heart. Since HNE increased proton
conductance in skeletal muscle and heart of Ucp3KO mice (also
reported for skeletal muscle in refs. [9,27]), its effect is not restricted
to UCP3, and other proteins must also be involved.
4.3. UCP3 and ANT contribute to differing degrees to HNE-induced
proton conductance in mitochondria from skeletal muscle and heart:
Speciﬁcity of GDP and carboxyatractylate
We studied the involvement of UCP3 and ANT in HNE-induced
proton conductance by using GDP and carboxyatractylate, classically
considered as speciﬁc blockers of UCPs and ANT, respectively.
However, the speciﬁcity of these inhibitors has recently been
questioned [37–39]. Both UCP3 and ANT contribute to the HNE-
induced increase in proton conductance in WT skeletal muscle, since
it was inhibited by both GDP and carboxyatractylate (Fig. 4A).
However, whereas the effect of GDP was partial, carboxyatractylateFig. 8. Effects of GDP (0.5 mM) and carboxyatractylate (CAT; 2.5 μM) on the rate of HNE-in
presence of 0.3% BSA. Experiments were performed in heart mitochondria from (A) Ucp3KO
interpolation at 150 mV. Data are means±SEM from 6 independent experiments, each
§§§Pb0.001 vs. Ucp3KO+HNE or Ucp3KO+LPS+HNE).completely abolished HNE-induced proton conductance, with no
additive effect of GDP [9]. As expected, the inhibitory effect of GDP
was higher in LPS-treated WT mice (Fig. 4B) than in WT animals
(Fig. 4A).
Given that GDP had no effect on HNE-induced proton conductance
in the skeletal muscle of Ucp3KO mice (Fig. 5A and B), we conclude
that, at least in muscle, GDP is speciﬁc for UCP3, in contrast to some
reported ﬁndings [37–39] but in agreement with others [9]. The
ability of carboxyatractylate to completely inhibit HNE effects in WT
muscle indicates that it blocks conductance via UCP3 and therefore is
not speciﬁc for ANT. A similar conclusion was reached by [38,39].
These authors proposed that carboxyatractylate might inhibit UCP3
through an unknown indirect mechanism, which would explain the
lack of additivity [38]. In LPS-treated WT mice, however, the addition
of both inhibitors was required to completely abolish HNE effects
(Fig. 4B). Interestingly, calorie restriction leads to greater proton
conductance possibly mediated by ANT in skeletal muscle mitochon-
dria from Ucp3KO compared to WT mice, which suggests a functional
interaction between UCP3 and ANT [39]. This kind of interaction,
however, does not seem to take place in the context of HNE activation,
since Ucp3KO mitochondria do not show enhanced proton conduc-
tance in response to HNE compared to WT mitochondria (Fig. 3A).
In the heart, GDP had no effect on HNE-induced proton
conductance, even in untreated WT mice (Fig. 7A) as also reported
in rat heart [9], or LPS-treated WT mice (Fig. 7B). This is surprising,
especially for LPS-treated mice, since these animals have increased
levels of UCP3 expression (Fig. 1C and D). This lack of effect might be
explained by the lower expression levels of UCP3 in the heart
compared with skeletal muscle [4]; and this might also explain why
the HNE-induced proton conductance of heart mitochondria did not
differ between WT and Ucp3KO mice. To our knowledge, this kind ofduced proton leak in Ucp3KO heart mitochondria. All measurements were made in the
and (B) and LPS-treated Ucp3KO mice. Bar graphs on the right show the proton leak by
performed in duplicate (*Pb0.05, ***Pb0.001 vs. Ucp3KO or Ucp3KO+LPS; §§Pb0.01,
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addition of carboxyatractylate partially inhibited HNE-stimulated
proton conductance in heart mitochondria, and no additive effect of
GDP was detected in any experimental group (Figs. 7 and 8).
Therefore, HNE-induced proton conductance in the heart involves
not only ANT but also proteins insensitive to carboxyatractylate and
GDP. The possibility that carboxyatractylate indirectly inhibits UCP3
in the heart cannot be excluded. An alternative explanation is that
HNE induces a conformational change in ANT that prevents, at least in
part, carboxyatractylate inhibition, as has recently been reported in
rat liver mitochondria [26]. Further studies are required in heart
mitochondria to clarify this point.
5. Conclusion
Our results support the idea that UCP3 contributes only minimally
to basal proton conductance of skeletal muscle mitochondria but not
of heart mitochondria, since altered UCP3 expression did not modify
basal proton conductance. HNE activates proton conductance in
skeletal muscle and heart mitochondria. This effect is partially
catalyzed by UCP3 (30%) and ANT (or other carriers sensitive to
carboxyatractylate) in skeletal muscle, whereas in the heart it is
catalyzed by ANT together with transporters insensitive to carboxya-
tractylate and GDP. While GDP speciﬁcally inhibits UCP3, at least in
muscle, carboxyatractylate is not speciﬁc for ANT and can act
indirectly on UCP3 and possibly on other mitochondrial carriers.
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